newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results and Provides an Update on Clinical Development Programs

NDA for Omaveloxolone for Patients With Friedreich's Ataxia Under Review With PDUFA Date of February 28, 2023 FDA Does Not Plan to Hold an Advisory Committee Meeting to Discuss the Omaveloxolone NDA and the Late Cycle